Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

ABSTRACT:

Purpose

Targeted inhibitors and immunotherapy have entered the treatment landscape of metastatic prostate cancer. Genomic testing may uncover which patients benefit most from these therapies. We report the clinical utility and benefits of FoundationOne testing in men with advanced prostate cancer.

Patients and methods

We retrospectively identified all men with prostate cancer who received tissue FoundationOne testing at our institution between January 2010 and April 2017. Genomic alterations, treatment selection based on FoundationOne results, and clinical outcomes including response and duration of therapy following matched targeted therapy were analyzed.

Results

A total of 77 men with metastatic prostate cancer were referred for FoundationOne testing; 59 (77%) had s

SUBMITTER: Zhu J 

PROVIDER: S-EPMC6823135 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature